The Alliance’s insulin glargine product is a basal insulin with the same amino acid sequence as Lantus (insulin glargine) and is intended to provide long-lasting blood sugar control between meals and at night. Lilly/Boehringer Ingelheim’s insulin glargine product will be available in a pre-filled pen and cartridges for a reusable pen.
The marketing authorization for this new insulin glargine product is based upon a comprehensive clinical data program, which showed it has similar efficacy and safety compared to the currently marketed insulin glargine product in people with type 1 and type 2 diabetes. The application included results from pharmacokinetic and pharmacodynamic studies, as well as Phase III studies in patients with type 1 and type 2 diabetes.
While ‘Abasria’ is an approved name for the product in Europe, it’s not necessarily approved in other regions. Lilly and Boehringer Ingelheim are targeting a global trade name for the Alliance’s insulin glargine product, which will be announced at a later date.